Staff Reports
In an unexpected twist, Democrat Representative Ro Khanna has stepped up to the plate, mirroring the wise decision-making of President Trump by introducing new legislation. Khanna is pushing to make Trump’s executive order on drug pricing a permanent law, much to the shock of many in his party. This is a moment where the Democrats are catching a glimpse of actual sense, mirroring Trump’s effort to stop Americans from being ripped off by Big Pharma.
Picture this: ordinary Americans are forced to pay through the nose for their medications while other countries get the same drugs for a fraction of the cost. It’s outrageous! For too long, this has been the sad reality, with Big Pharma laughing all the way to the bank while American families suffer. Trump recognized this glaring injustice and took direct action with his executive order, targeting unfair global practices and demanding most-favored-nation pricing for American consumers.
When we won this election back in November for President Trump. We knew that the establishment was going to elect weak leadership in Speaker Johnson and Senator John Thune. Two anti-Trumpers. I am not worried about democrats right now because republicans cannot seem to find their… pic.twitter.com/Wfligxt3Tt
— Matthew Zimmerman 🇺🇸 (@MattZimmerman26) May 14, 2025
Why should the United States, the world’s largest drug market, subsidize socialist healthcare in other nations? It’s madness! American citizens end up paying more for the same pills, lining the pockets of pharmaceutical giants who couldn’t care less about the hardworking men and women in this country. The “most-favored-nation” pricing initiative outlined by Trump is a key strategy, aiming to ensure Americans only pay fair prices for their prescriptions.
But Khanna isn’t stopping at mere executive orders that Big Pharma could challenge in court. He is bringing this vision to law to avoid the legal traps and tirades of greedy pharmaceutical companies. This bold move demands our attention. By introducing this legislation, Khanna, despite being a Democrat, is daring to stand up against the usual left-wing pandering. Will his fellow Democrats have the courage to back him, or will they continue to pocket Big Pharma’s dirty dollars?
This moment draws a line in the sand. Will Congress put the American people first, or will they continue to dance to the tune of international socialist superiority? Congress must step up, back this brave move, and finally put an end to the unfairness that has plagued American drug pricing for far too long. The question remains: are they ready to put their money where their mouth is, or will they buckle under pressure?
